414 related articles for article (PubMed ID: 34905129)
21. The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies.
Robak P; Witkowska M; Wolska-Washer A; Robak T
Expert Opin Drug Discov; 2023; 18(10):1065-1076. PubMed ID: 37438969
[TBL] [Abstract][Full Text] [Related]
22. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
De SK
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37818564
[TBL] [Abstract][Full Text] [Related]
23. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
Alu A; Lei H; Han X; Wei Y; Wei X
J Hematol Oncol; 2022 Oct; 15(1):138. PubMed ID: 36183125
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
Lucas F; Woyach JA
Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
[TBL] [Abstract][Full Text] [Related]
25. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
26. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
[TBL] [Abstract][Full Text] [Related]
27. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
28. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Spriano F; Tarantelli C; Gaudio E; Gerlach MM; Priebe V; Cascione L; Bernasconi E; Targa A; Mascia M; Dirnhofer S; Stathis A; Zucca E; Bertoni F
Br J Haematol; 2019 Dec; 187(5):595-601. PubMed ID: 31355927
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M
Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814
[TBL] [Abstract][Full Text] [Related]
30. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
31. Tirabrutinib hydrochloride for B-cell lymphomas.
Munakata W; Tobinai K
Drugs Today (Barc); 2021 Apr; 57(4):277-289. PubMed ID: 33851691
[TBL] [Abstract][Full Text] [Related]
32. Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
Lin DY; Andreotti AH
PLoS One; 2023; 18(8):e0290872. PubMed ID: 37651403
[TBL] [Abstract][Full Text] [Related]
33. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
[TBL] [Abstract][Full Text] [Related]
34. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
35. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
Gu D; Tang H; Wu J; Li J; Miao Y
J Hematol Oncol; 2021 Mar; 14(1):40. PubMed ID: 33676527
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.
Christensen BW; Zaha VG; Awan FT
Expert Rev Hematol; 2022 Apr; 15(4):321-331. PubMed ID: 35437106
[TBL] [Abstract][Full Text] [Related]
37. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Palma M; Mulder TA; Österborg A
Front Immunol; 2021; 12():686768. PubMed ID: 34276674
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
39. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
40. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
Dostálová H; Kryštof V
Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
